// App-Quantinova.ai

216 : Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Researchers

Presenter

  • Ning Li

Principal Investigators

  • Zhi Li

  • Qiang Fu

  • Bin Zhang

  • Jian Zhang

  • XiangBin Wan

  • Chaomin Lu

  • Jinbang Wang

  • Wenying Deng

  • Chen Wei

  • Yijie Ma

  • Liangyu Bie

  • Mengyu Wang

  • Suxia Luo

Medical Centers

  • Department of Interventional Radiology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

  • Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

  • Henan Cancer Hospital, Zhengzhou, China

  • Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

  • Department of Medical Oncology, Zhejiang Cancer Hospital, Zhejiang, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Fluorouracil

  • Adrucil injection

  • Oxaliplatin

  • leucovorin

  • Sintilimab

  • Docetaxel

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • II

Study Id's

  • NCT04341857

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved